A thirteen-gene expression signature predicts survival of patients with pancreatic cancer and identifies new genes of interest

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Newhook, Timothy E ^a   Blais, Edik M ^b   Lindberg, James M ^a   Adair, Sara J ^a   Xin, Wenjun ^c   Lee, Jae K ^c   Papin, Jason A ^b   Parsons, J Thomas ^a   Bauer, Todd W ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b University of Virginia   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CD200 RECEPTOR; GEMCITABINE; HU ANTIGEN; PHOSPHOLIPASE C; PROTEIN KINASE C; PROTEIN MDM2; RNA BINDING PROTEIN; TRANSFORMING GROWTH FACTOR ALPHA; VASCULAR ENDOTHELIAL CADHERIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CCDC88C GENE; CD200R1 GENE; CDH5 GENE; CONTROLLED STUDY; CUL3 GENE; ELAVL1 GENE; FAM80B GENE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC RISK; HUMAN; HUMAN TISSUE; LOC149134 GENE; MAJOR CLINICAL STUDY; MALE; MDM2 GENE; MOUSE; MS4A3 GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PLCG1 GENE; PREDICTION; PRKCSH GENE; PROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; SURVIVAL TIME; TGFA GENE; TUMOR XENOGRAFT; ULBP3 GENE; ADENOCARCINOMA; GENE EXPRESSION REGULATION; GENETICS; LYMPH NODE; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; REPRODUCIBILITY; SIGNAL TRANSDUCTION; SURVIVAL; TUMOR GENE; UPREGULATION;

ADENOCARCINOMA; CARCINOMA, PANCREATIC DUCTAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; LYMPH NODES; PANCREATIC NEOPLASMS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; UP-REGULATION;

EID: 84907459320     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105631     Document Type: Article

References (58)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA: a cancer journal for clinicians 62: 10-29.
2. Cameron JL, Riall TS, Coleman J, Belcher KA (2006) One thousand consecutive pancreaticoduodenectomies. Annals of surgery 244: 10-15. (Pubitemid 44297442)
3. Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17: 1471-1474.
4. Geer RJ, Brennan MF (1993) Prognostic indicators for survival after resection of pancreatic adenocarcinoma. American journal of surgery 165: 68-72; discussion 72-63.
5. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, et al. (2000) Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 4: 567-579.
6. Weber CE, Bock EA, Hurtuk MG, Abood GJ, Pickleman J, et al. (2014) Clinical and pathologic features influencing survival in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma. J Gastrointest Surg 18: 340-347.
7. National Research Council (U.S.). Committee for the Update of the Guide for the Care and Use of Laboratory Animals., Institute for Laboratory Animal Research (U.S.), National Academies Press (U.S.) (2011) Guide for the care and use of laboratory animals. Washington, D.C.: National Academies Press. xxv, 220 p. p.
8. Stokes JB, Adair SJ, Slack-Davis JK, Walters DM, Tilghman RW, et al. (2011) Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Molecular Cancer Therapeutics 10: 2135-2145.
9. Walters DM, Stokes JB, Adair SJ, Stelow EB, Borgman CA, et al. (2013) Clinical, molecular and genetic validation of a murine orthotopic xenograft model of pancreatic adenocarcinoma using fresh human specimens. PloS one 8: e77065.
10. Kanehisa M, Goto S, Sato Y, Kawashima M, Furumichi M, et al. (2014) Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res 42: D199-205.
11. Kanehisa M, Goto S (2000) KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28: 27-30. (Pubitemid 30047706)
12. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545-15550. (Pubitemid 41528093)
13. Yamabuki T, Daigo Y, Kato T, Hayama S, Tsunoda T, et al. (2006) Genomewide gene expression profile analysis of esophageal squamous cell carcinomas. Int J Oncol 28: 1375-1384.
14. Smyth GK (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3.
15. Hanzelmann S, Castelo R, Guinney J (2013) GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 14: 7.
16. Stratford JK, Bentrem DJ, Anderson JM, Fan C, Volmar KA, et al. (2010) A sixgene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma. PLoS medicine 7: e1000307.
17. Bilimoria KY, Bentrem DJ, Ko CY, Ritchey J, Stewart AK, et al. (2007) Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer 110: 738-744. (Pubitemid 47257648)
18. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801-1806.
19. Donahue TR, Tran LM, Hill R, Li Y, Kovochich A, et al. (2012) Integrative survival-based molecular profiling of human pancreatic cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 18: 1352-1363.
20. Kim HN, Choi DW, Lee KT, Lee JK, Heo JS, et al. (2007) Gene expression profiling in lymph node-positive and lymph node-negative pancreatic cancer. Pancreas 34: 325-334. (Pubitemid 46588258)
21. Knezevic D, Goddard AD, Natraj N, Cherbavaz DB, Clark-Langone KM, et al. (2013) Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genomics 14: 690.
22. Clark-Langone KM, Sangli C, Krishnakumar J, Watson D (2010) Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX Colon Cancer Assay. BMC Cancer 10: 691.
23. Cronin M, Sangli C, Liu ML, Pho M, Dutta D, et al. (2007) Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem 53: 1084-1091. (Pubitemid 46867525)
24. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536. (Pubitemid 34130608)
25. Paik S, Shak S, Tang G, Kim C, Baker J, et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. The New England journal of medicine 351: 2817-2826. (Pubitemid 40051905)
26. Cardoso F, Piccart-Gebhart M, Van't Veer L, Rutgers E (2007) The MINDACT trial: the first prospective clinical validation of a genomic tool. Mol Oncol 1: 246-251. (Pubitemid 350181650)
27. Jansen MP, Foekens JA, van Staveren IL, Dirkzwager-Kiel MM, Ritstier K, et al. (2005) Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 23: 732-740.
28. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, et al. (2004) Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 22: 2284-2293.
29. Folgueira MA, Carraro DM, Brentani H, Patrao DF, Barbosa EM, et al. (2005) Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 11: 7434-7443.
30. Hannemann J, Oosterkamp HM, Bosch CA, Velds A, Wessels LF, et al. (2005) Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 23: 3331-3342.
31. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, et al. (2003) Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362: 362-369. (Pubitemid 36957839)
32. Siveke JT, Einwachter H, Sipos B, Lubeseder-Martellato C, Kloppel G, et al. (2007) Concomitant pancreatic activation of Kras(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN. Cancer Cell 12: 266-279. (Pubitemid 47333415)
33. Costantino CL, Witkiewicz AK, Kuwano Y, Cozzitorto JA, Kennedy EP, et al. (2009) The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Upregulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase. Cancer Research 69: 4567-4572.
34. Ebert M, Yokoyama M, Kobrin M, Friess H, Buchler M, et al. (1994) Increased mdm2 expression and immunoreactivity in human pancreatic ductal adenocarcinoma. Int J Oncol 5: 1279-1284. (Pubitemid 24357471)
35. Kutok JL, Yang X, Folkerth R, Adra CN (2011) Characterization of the expression of HTm4 (MS4A3), a cell cycle regulator, in human peripheral blood cells and normal and malignant tissues. Journal of Cellular and Molecular Medicine 15: 86-93.
36. Sui X, Shin S, Zhang R, Firozi PF, Yang L, et al. (2009) Hdm2 is regulated by K-Ras and mediates p53-independent functions in pancreatic cancer cells. Oncogene 28: 709-720.
37. Long J, Zhang B, Signorello LB, Cai Q, Deming-Halverson S, et al. (2013) Evaluating genome-wide association study-identified breast cancer risk variants in african-american women. PLoS One 8: e58350.
38. Stumpfova M, Ratner D, Desciak EB, Eliezri YD, Owens DM (2010) The immunosuppressive surface ligand CD200 augments the metastatic capacity of squamous cell carcinoma. Cancer Res 70: 2962-2972.
39. Grau L, Luque-Garcia JL, Gonzalez-Peramato P, Theodorescu D, Palou J, et al. (2013) A quantitative proteomic analysis uncovers the relevance of CUL3 in bladder cancer aggressiveness. PloS one 8: e53328.
40. Hollstein PE, Cichowski K (2013) Identifying the ubiquitin ligase complex that regulates the NF1 tumor suppressor and Ras. Cancer Discov.
41. Emick DM, Riall TS, Cameron JL, Winter JM, Lillemoe KD, et al. (2006) Hospital readmission after pancreaticoduodenectomy. J Gastrointest Surg 10: 1243-1252; discussion 1252-1243.
42. Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, et al. (1997) Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Annals of surgery 226: 248-257; discussion 257-260.
43. Fong ZV, Ferrone CR, Thayer SP, Wargo JA, Sahora K, et al. (2013) Understanding Hospital Readmissions After Pancreaticoduodenectomy: Can We Prevent Them? : A 10-Year Contemporary Experience with 1,173 Patients at the Massachusetts General Hospital. J Gastrointest Surg.
44. Valsangkar NP, Morales-Oyarvide V, Thayer SP, Ferrone CR, Wargo JA, et al. (2012) 851 resected cystic tumors of the pancreas: a 33-year experience at the Massachusetts General Hospital. Surgery 152: S4-12.
45. Tonks A, Hills R, White P, Rosie B, Mills KI, et al. (2007) CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 21: 566-568.
46. Moreaux J, Hose D, Reme T, Jourdan E, Hundemer M, et al. (2006) CD200 is a new prognostic factor in multiple myeloma. Blood 108: 4194-4197. (Pubitemid 44913292)
47. Speisky D, Duces A, Bieche I, Rebours V, Hammel P, et al. (2012) Molecular profiling of pancreatic neuroendocrine tumors in sporadic and Von Hippel-Lindau patients. Clinical cancer research : an official journal of the American Association for Cancer Research 18: 2838-2849.
48. Rezaei M, Friedrich K, Wielockx B, Kuzmanov A, Kettelhake A, et al. (2012) Interplay between neural-cadherin and vascular endothelial-cadherin in breast cancer progression. Breast Cancer Res 14: R154.
49. Craig DW, O'Shaughnessy JA, Kiefer JA, Aldrich J, Sinari S, et al. (2013) Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities. Molecular cancer therapeutics 12: 104-116.
50. Yuan Z, Sanders AJ, Ye L, Wang Y, Jiang WG (2011) Prognostic value of the human antigen R (HuR) in human breast cancer: high level predicts a favourable prognosis. Anticancer Res 31: 303-310.
51. Yuan Z, Sanders AJ, Ye L, Wang Y, Jiang WG (2011) Knockdown of human antigen R reduces the growth and invasion of breast cancer cells in vitro and affects expression of cyclin D1 and MMP-9. Oncol Rep 26: 237-245.
52. Lim SJ, Kim HJ, Kim JY, Park K, Lee CM (2007) Expression of HuR is associated with increased cyclooxygenase-2 expression in uterine cervical carcinoma. Int J Gynecol Pathol 26: 229-234. (Pubitemid 46986054)
53. Wang J, Wang B, Bi J, Zhang C (2011) Cytoplasmic HuR expression correlates with angiogenesis, lymphangiogenesis, and poor outcome in lung cancer. Med Oncol 28 Suppl 1: S577-585.
54. Wade M, Li YC, Wahl GM (2013) MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nature reviews Cancer 13: 83-96.
55. Kassis J, Moellinger J, Lo H, Greenberg NM, Kim HG, et al. (1999) A role for phospholipase C-gamma-mediated signaling in tumor cell invasion. Clinical cancer research : an official journal of the American Association for Cancer Research 5: 2251-2260.
56. Arteaga CL, Johnson MD, Todderud G, Coffey RJ, Carpenter G, et al. (1991) Elevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in primary human breast carcinomas. Proceedings of the National Academy of Sciences of the United States of America 88: 10435-10439. (Pubitemid 21915850)
57. Serao NV, Delfino KR, Southey BR, Beever JE, Rodriguez-Zas SL (2011) Cell cycle and aging, morphogenesis, and response to stimuli genes are individualized biomarkers of glioblastoma progression and survival. BMC Med Genomics 4: 49.
58. Poggi A, Venturino C, Catellani S, Clavio M, Miglino M, et al. (2004) Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. Cancer Res 64: 9172-9179. (Pubitemid 39665533)